{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085865","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.799371+00:00","generated_at":"2026-06-24T03:55:28.389146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated","bullets":["GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.","LINZESS EUTRx prescription demand grew 9% year-over-year in Q2 2022.","Completed $75M share repurchase program and repaid remaining 2022 Convertible Notes in cash.","Reiterated 2022 guidance: low single-digit % LINZESS net sales growth, total revenue $420-$430M, adjusted EBITDA >$250M.","Phase 3 pediatric linaclotide study for functional constipation expected to readout in Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085865","json":"https://secwatch.observer/filing/0001104659-22-085865.json","markdown":"https://secwatch.observer/filing/0001104659-22-085865.md","text":"https://secwatch.observer/filing/0001104659-22-085865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/0001104659-22-085865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922085865/tm2222410d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:55:28.389146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}